[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
April 22, 1992

High 10-Year Survival Rate in Patients With Early, Untreated Prostatic Cancer

Author Affiliations

From the Department of Urology, Örebro (Sweden) Medical Center Hospital (Drs Johansson and Andersson); Cancer Epidemiology Unit, Uppsala (Sweden) University Hospital (Drs Johansson, Adami, and Holmberg); Department of Statistics, Uppsala University (Dr Bergström); Department of Surgery, Uppsala University Hospital (Dr Holmberg); and Uppsala University Data Center (Ms Krusemo).

JAMA. 1992;267(16):2191-2196. doi:10.1001/jama.1992.03480160049033
Abstract

Objective.  —To learn about the natural history of untreated, early-stage prostatic cancer.

Design.  —Cohort study with a mean follow-up of 123 months (range, 81 to 165 months).

Setting.  —Population-based, regionally well defined.

Patients.  —A consecutive sample of 223 patients (98% of all eligible) with earlystage (T0-2, NX, MO), initially untreated prostatic cancer.

Main Outcome Measures.  —Progression-free, disease-specific, and overall survival. Need for palliative and terminal care.

Intervention.  —Patients with tumor progression were hormonally treated (orchiectomy or estrogens) if they had symptoms.

Results.  —After complete follow-up, only 19 (8.5%) of the 223 patients had died of prostate cancer and 105 (85%) of a total of 124 deaths were from other causes. The 10-year, disease-specific survival rate was 86.8% (95% confidence interval, 80.7% to 92.9%) and was equally high (87.9%) in a subgroup of 58 patients who met current indications for radical prostatectomy. The progression-free, 10-year survival rate was 53.1% (95% confidence interval, 44.2% to 62.0%). In 50 of 76 patients, local growth provided the only evidence of progression, and endocrine treatment was generally successful in these cases. Following an initial increase, the rate of disease progression and death from prostate cancer decreased during the last years of follow-up.

Conclusion.  —The low disease-specific mortality rate, especially in patients with highly and moderately differentiated tumors, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.(JAMA. 1992;267:2191-2196)

References
1.
Johansson J-E, Adami H-O, Andersson S-O, Bergström R, Krusemo UB, Kraaz W.  Natural history of localised prostatic cancer: a population-based study in 223 untreated patients. Lancet . 1989;1:799-803.Article
2.
Bakke A, Grong K, Höisaetre PÅ.  Should we treat localized prostatic cancer?  In: Proceedings of the 1985 Finnish Urological Club Meeting, March 1,1985 . Printao, Finland: Finnish Urological Club; 1985:58-65.
3.
Larsson A, Norlen BJ.  Five-year follow-up of patients with localized prostatic carcinoma initially referred for expectant treatment. Scand J Urol Nephrol . 1985;19( (suppl 93) ):30.
4.
Adolfsson J, Rönström L, Hedlund PO, Löwhagen T, Carstensen J, Tribukait B.  The prognostic value of nodal deoxyribonucleic acid in low grade, low stage untreated prostate cancer. J Urol (Paris) . 1990;144:1404-1407.
5.
George NJR.  Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet . 1988;1:494-497.Article
6.
Handley R, Carr TW, Travis D, Powell PH, Hall RR.  Deferred treatment for prostate cancer. Br J Urol . 1988;62:249-253.Article
7.
Madsen PO, Graversen PH, Gasser TC, Corle DK.  Treatment of localized prostatic cancer. Radical prostatectomy versus placebo: a 15 year follow-up. Scand J Urol Nephrol . 1988;110:95-100.
8.
Muskovitz B, Nitecki S, Levin DR.  Cancer of prostate: is there a need for aggressive treatment. Urol Int . 1987;42:49-52.Article
9.
Whitmore WF Jr, Warner JA, Thompson IM.  Expectant management of localized prostatic cancer. Cancer . 1991;67:1091-1096.Article
10.
Union Internationale Contre le Cancer. TNM Classification of Malignant Tumours . 3rd ed. Geneva, Switzerland: International Union Against Cancer; 1978.
11.
World Health Organization. International Histological Classification of Tumours: Histological Typing of Prostate Tumours . Geneva, Switzerland: World Health Organization; 1980; No. 22.
12.
Schmidt JD, Gibbons RP, Johnson DE, Prout GR, Scott WW, Murphy GP.  Chemotherapy of advanced prostatic cancer: evaluation of response parameters. Urology . 1976;7:602-611.Article
13.
Karnofsky DA, Burchenal JH.  The clinical of chemotherapeutic agents in cancer.  In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents . New York, NY: Columbia University Press; 1946.
14.
Cutler SJ, Ederer F.  Maximum utilization of the life table method in analyzing survival. J Chronic Dis . 1958;8:699-710.Article
15.
Ederer F, Axtell IM, Cutler SJ.  The relative survival rate: a statistical methodology. Monogr Natl Cancer Inst . 1961;6:101-121.
16.
Hakulinen T.  On long-term relative survival rates. J Chronic Dis . 1977;30:431-443.Article
17.
Cox DR.  Regression model and life tables. JR Stat Soc . 1972;B34:187-220.
18.
Esposti PL.  Cytological malignancy grading of prostatic carcinoma by transrectal aspiration biopsy: a five-year follow-up study of 469 hormone-treated patients. Scand J Urol Nephrol . 1971;5: 199-209.Article
19.
Hostetter AL, Pedersen KV, Gustafsson BL, Månson J-C, Boeryd BRG.  Diagnosis and localization of prostate carcinoma by fine-needle aspiration cytology and correlation with histologic whole-organ sections after radical prostatectomy. Am J Clin Pathol . 1990;94:693-697.
20.
Gervasi LA, Mata JA, Scardino PT.  The prognostic significance of the extent of nodal metastases in prostatic cancer. J Urol . 1989;142:332-336.
21.
Corriere JN Jr, Cornog JL, Murphy JJ.  Prognosis in patients with carcinoma of the prostate. Cancer . 1970;25:911-918.Article
22.
Hanash KA, Utz DC, Cooke EN, Taylor WF, Titus JL.  Carcinoma of the prostate: a 15 year follow-up. J Urol . 1972;107:450-453.
23.
Scardino PT.  Early detection of prostate cancer. Urol Clin North Am . 1989;16:635-655.
24.
Bagshaw MA.  Potential for radiotherapy alone in prostatic cancer. Cancer . 1985;55:2079-2085.Article
25.
Gibbons RP, Correa RJ, Brannen GE, Weissman RM.  Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol . 1989;141:564-566.
26.
Middleton RG, Larsen RH.  Selection of patients with stage B prostate cancer for radical prostatectomy. Urol Clin North Am . 1990; 17:779-785.
27.
Whitmore WF Jr.  Overview: historical and contemporary. Monogr Natl Cancer Inst . 1988;7:7-11.
×